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Stimulator of Interferon Genes (STING) is a critical
component of host innate immune defense but
can contribute to chronic autoimmune or autoin-
flammatorydisease.Onceactivated, thecyclicguano-
sine monophosphate (GMP)-adenosine monophos-
phate (AMP) (cGAMP) synthase (cGAS)-STING
pathway induces both type I interferon (IFN) expres-
sion and nuclear factor-kB (NF-kB)-mediated
cytokine production. Currently, these two signaling
arms are thought to bemediated by a single upstream
kinase, TANK-binding kinase1 (TBK1). Here, usingge-
netic and pharmacological approaches, we show that
TBK1 alone is dispensable for STING-induced NF-kB
responses in human and mouse immune cells, as
well as in vivo. We further demonstrate that TBK1
acts redundantly with IkB kinase ε (IKKε) to drive NF-
kB upon STING activation. Interestingly, we show
that activationof IFN regulatory factor 3 (IRF3) is highly
dependent on TBK1 kinase activity, whereas NF-kB
is significantly less sensitive to TBK1/IKKε kinase inhi-
bition. Our work redefines signaling events down-
stream of cGAS-STING. Our findings further suggest
that cGAS-STING will need to be targeted directly to
effectively ameliorate the inflammation underpinning
disorders associated with STING hyperactivity.
INTRODUCTION
The innate immune system induces a rapid response following
the recognition of pathogens or endogenous danger signals by
stimulating the release of inflammatory mediators. This response
is facilitated by families of highly conserved pattern recognition
receptors (PRRs) that are expressed by innate immune cells,
such as macrophages and dendritic cells (De Nardo, 2017).
Once activated, many PRRs initiate downstream signaling cas-
cades, leading to the secretion of cytokines, chemokines, and in-
terferons (IFNs), producing a local inflammatory milieu, the
recruitment of additional immune cells, and ultimately the resolu-
tion of the insult and initiation of tissue repair. Nucleic acid
sensing PRRs are particularly important for initiating an anti-viral
immune response following infection. There are two major cyto-
solic sensors for double-stranded DNA (dsDNA): the inflamma-
some-forming protein absent in melanoma-2 (AIM2), which
induces maturation of the cytokines interleukin-1b (IL-1b) and
IL-18 and an inflammatory form of cell death known as pyropto-
sis (Latz et al., 2013); and cyclic guanosine monophosphate
(GMP)-adenosine monophosphate (AMP) (cGAMP) synthase
(cGAS), which is important for inducing a potent type I IFN
response to viral infection. cGAS is unique among PRRs due to
its enzymatic activity as a nucleotidyl transferase that cyclizes
ATP and GTP by phosphodiester bonds, resulting in the forma-
tion of the endogenous cyclic dinucleotide (CDN) 2030-cGAMP
(Ablasser et al., 2013; Diner et al., 2013; Sun et al., 2013; Zhang
et al., 2013). 2030-cGAMP then acts as a specific second
messenger to activate the endoplasmic reticulum (ER)-resident
protein Stimulator of Interferon Genes (STING). Although 2030-
cGAMP is the only known mammalian CDN, similar CDNs
(e.g., 303’-cGAMP, cyclic-di-AMP, cyclic-di-GMP) are released
from bacteria during infection that can also bind directly to
STING and induce its activation (Burdette et al., 2011; McWhirter
et al., 2009; Woodward et al., 2010). The absolute requirement of
STING for mediating an anti-viral immune response against DNA
viruses, such as herpes simplex virus-1 (HSV-1), has been
demonstrated through the use of cGAS- and STING-deficient
mice (Ishikawa et al., 2009; Li et al., 2013). On the other hand,
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the induction of type I IFNs by STING can have unfavorable ef-
fects in the context of bacterial infection (e.g., Listeria monocyto-
genes) by promoting bacterial growth and survival (Marinho
et al., 2017).
The inability of cGAS to precisely discriminate the origin and
length of dsDNA that it encounters also enables sensing of mis-
localized host-derived dsDNA in the cytosol, such as genomic or
mitochondrial DNA (Rongvaux et al., 2014; West et al., 2015;
White et al., 2014). Hence the cGAS-STING pathway is patho-
genic in primary immune disorders associated with an accumu-
lation of cytosolic self-DNA, including Aicardi-Goutie`res syn-
drome and certain forms of lupus (Ablasser et al., 2014; Ahn
et al., 2012; Gall et al., 2012; Gkirtzimanaki et al., 2018). Recent
work has suggested that failure to induce mitophagy (the pro-
cess of removing damaged mitochondria) leads to excessive
circulating mtDNA that can elicit aberrant inflammation via
cGAS-STING and contribute to aging-related neurodegenerative
conditions, such as Parkinson’s disease (Sliter et al., 2018).
Perhaps the clearest demonstration of the importance of con-
trolling STING signaling was the identification of a life-threat-
ening autoinflammatory condition, termed STING-associated
vasculopathy with onset in infancy (SAVI) (Liu et al., 2014). The
chronic inflammation observed in SAVI patients was found to
be driven by de novo autoactivating mutations in TMEM173
(the gene encoding STING), leading to constitutive STING activa-
tion that manifests early in life as inflammatory skin lesions,
small-vessel vasculitis, and in some cases, severe pulmonary
complications (Clarke et al., 2016; Liu et al., 2014).
To date, the majority of studies examining cGAS-STING
have focused primarily on the potent type I IFN response;
however, STING also triggers a prominent pro-inflammatory
cytokine response (e.g., tumor necrosis factor [TNF], IL-1b,
and IL-6) through the activity of NF-kB (Ishikawa and Barber,
2008; Ishikawa et al., 2009). CDN binding induces significant
conformational changes in preformed STING dimers, initiating
translocation from the ER to Golgi compartments and the
recruitment of the serine-threonine protein kinase, TANK-bind-
ing kinase 1 (TBK1). TBK1 subsequently phosphorylates resi-
dues in the C-terminal tail (CTT) region of STING, allowing
the recruitment of IFN regulatory factor 3 (IRF3) molecules
and their subsequent phosphorylation by TBK1 (Liu et al.,
2015; Tanaka and Chen, 2012). Activated IRF3 dimers then
translocate to the nucleus and induce the expression and
secretion of type I IFNs (e.g., IFNb), which in turn leads to
the production of numerous IFN-stimulated genes (ISGs),
inducing a robust anti-viral state. In addition, NF-kB, along
with other transcription factors, synergizes with IRF3 by
collectively binding a specific enhancer region within the
IFNb promoter, termed the enhanceosome, resulting in
maximal IFNb expression (Smale, 2010). Currently, it is widely
accepted that in addition to eliciting the type I IFN response,
TBK1 is also responsible for inducing NF-kB activation down-
stream of STING, as demonstrated in TBK1-deficient and
TBK1 RNAi-silenced mouse embryonic fibroblasts (MEFs)
(Abe and Barber, 2014).
Both TBK1 and its homolog, IkB kinase (IKK) ε (IKKε, also
known as IKKi), were initially found to induceNF-kB luciferase re-
porter activity in overexpression studies (Shimada et al., 1999;
Tojima et al., 2000). However, experiments using Tbk1–/–,
IKKε–/–, and Tbk1–/–/IKKε–/– mice or TBK1/IKKε chemical inhibi-
tion have demonstrated that although TBK1, and to a much
lesser extent IKKε, have an essential role in IRF3-mediated
IFNb production, they are not required for NF-kB activation in
response to Toll-like receptors (TLRs), IL-1b, or TNF (Clark
et al., 2009; Hemmi et al., 2004; Perry et al., 2004). Several addi-
tional lines of evidence suggest that STING may induce NF-kB
activity via a TBK1-independent mechanism. First, the cGAS-
STING pathway predates the evolutionary emergence of IFNs,
suggesting it may have originally evolved as an activator of NF-
kB signaling. Second, despite the highly conserved nature of
STING across phyla, the presence of the CTT region, critical to
IFN induction, is observed only in vertebrates (Margolis et al.,
2017). Therefore, although physiological Drosophila mela-
nogaster and Nematostella vectensis STING can induce only
pathways homologous to NF-kB, the addition of the CTT of hu-
man STING to either species confers the ability to trigger type I
IFN activity (Kranzusch et al., 2015; Martin et al., 2018). Several
studies have further shown that removal of a part or the entire
CTT of human STING ablates IFN activity, but not that of NF-
kB (Cerboni et al., 2017; Chen et al., 2014). Third, STING is
known to be heavily modified posttranslationally, including via
phosphorylation, palmitoylation, ubiquitination, and SUMOyla-
tion (Baker et al., 2017). Although certain STING modifications,
such as palmitoylation, have been shown to be critical for both
type I IFN and NF-kB responses (Haag et al., 2018), ubiquitina-
tion of STING at lysine (K) residues 244 and 288 is specifically
required for trafficking of STING from the ER to the Golgi, where
it elicits type I IFN production (Ni et al., 2017; Stempel et al.,
2019). In contrast, STING-mediated NF-kB responses appear
to be independent of K244 and K288 ubiquitination, demon-
strating that these responsesmay occur prior to Golgi relocaliza-
tion, suggesting that spatial uncoupling of type I IFN and NF-kB
signaling can occur (Ni et al., 2017; Stempel et al., 2019). Further-
more, Konno et al. (2013) found that phosphorylation of STING at
serine residues 358 and 366, although critical for IRF3 activation,
was unnecessary for NF-kB activity. Finally, Dunphy et al. (2018)
demonstrated that DNA damage induced by the chemothera-
peutic agent etoposide elicits non-canonical STING activation
that primarily promotes NF-kB in a TBK1-independent manner,
rather than an IRF3 response. These observations raise the crit-
ical question of whether TBK1 alone directs STING-mediated
NF-kB responses.
Here, utilizing both genetic deletion and pharmacological
inhibition of TBK1 in murine and human innate immune cells,
we demonstrate that although TBK1 and its kinase activity are
critical for the phosphorylation of IRF3 and subsequent produc-
tion of IFNb in response to STING activation, NF-kB activity
and pro-inflammatory cytokine production can occur in a
manner independent of TBK1. We further show that STING-
NF-kB responses are actually mediated via a TBK1/IKKε redun-
dant mechanism. Based on these observations, we present a
revised model of STING signaling events leading to type I IFN
and NF-kB responses. Our findings shed light on the molecular
mechanisms of cGAS-STING signaling and have important
implications for the effective therapeutic targeting of cGAS-
STING-related diseases.
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RESULTS
Primary Macrophages Deficient in TBK1 Exhibit Normal
STING-NF-kB Responses
TBK1 is thought to be essential for STING-induced NF-kB acti-
vation; however, this has been formally shown only in MEFs
(Abe and Barber, 2014). Hence we first assessed STING re-
sponses in primary macrophages and mice deficient in TBK1.
Deletion of TBK1 induces embryonic lethality in mice (Bonnard
et al., 2000; Lafont et al., 2018; Xu et al., 2018); we therefore
utilized mice carrying floxed alleles of Tbk1 (Tbk1fl/fl) and
crossed these to ROSA26-CreERT2 (RosaCre) animals, allow-
ing for inducible ubiquitous in vivo deletion of Tbk1 upon treat-
ment with tamoxifen. We generated primary bone marrow-
derived macrophages (BMDMs) from tamoxifen-treated
Tbk1fl/fl (wild-type [WT]) and Tbk1fl/fl 3 RosaCre (TBK1
knockout [KO]) mice, observing significant depletion in levels
of TBK1 protein expression, albeit variable in cells from individ-
ual TBK1 KO animals (Figures 1A and S1). Of note, TBK1-defi-
cient primary BMDMs treated with DMXAA or 2030-cGAMP ex-
hibited reduced phosphorylation of IRF3 (p-IRF3) and STING
(p-STING) compared with their WT counterparts, whereas the
activation of NF-kB p65 (p-p65) and IkBa degradation re-
mained normal (Figures 1A and S1). We next treated primary
WT and TBK1 KO BMDMs with several activators of STING
(DMXAA, 2030-cGAMP) or cGAS-STING (DNA isolated from her-
ring testes [HT-DNA], HSV-1) and directly compared their ability
to produce IFNb and TNF protein. Significant reductions in IFNb
secretion in response to STING activation were clear from
TBK1-deficient BMDMs in response to all stimuli (Figure 1B),
whereas TNF levels were similar to those produced from WT
cells in response to direct STING activation with DMXAA and
cGAMP (Figure 1C). Interestingly, TBK1-deficient BMDMs did
show a consistent reduction in TNF in response to HT-DNA
and HSV-1, albeit not to statistically significant levels (Fig-
ure 1C). These data demonstrate that NF-kB responses are
maintained in TBK1-deficient macrophages upon STING acti-
vation, whereas in contrast, IRF3 activity and IFNb secretion
are significantly reduced.
TBK1-Deficient Mice Maintain NF-kB Responses
following DMXAA Challenge
To determine whether TBK1 is required for STING-NF-kB
signaling in vivo, we pre-treated Tbk1fl/fl (WT) and Tbk1fl/fl 3 Ro-
saCre (TBK1 KO) mice for 4 days with tamoxifen to induce Tbk1
gene deletion before acute challenge with DMXAA or a vehicle
control (Ctrl). Intraperitoneal injection of DMXAA led to increased
expression of type I IFNs and inflammatory cytokine genes
measured from WT spleens. TBK1 deficiency significantly
reduced expression of Ifna1, Ifna4, and Isg15, with a similar trend
in Ifnb1 (Figures 2A–2D). In contrast, the expression levels of the
NF-kB-dependent genes, Il1b, Il6, and Ccl4, were not reduced
(Figures 2E–2H). Of note, Tnf expression levels from mice defi-
cient in TBK1 appeared to decrease, albeit not significantly
(Figure 2H). This is in line with recent findings demonstrating
that in response to STING activation, a conventional dendritic
cells subset (cDC2) elicits TNF production in an NF-kB-indepen-
dent but TBK1-dependent manner in vivo (Mansouri et al., 2019).
Thus, the expression of TNF may not be a clear readout of
STING-mediated NF-kB activity in vivo. Consistent with our
findings in vitro, these data show that in vivo, the induction of
NF-kB-dependent responses downstream of STING activation
can occur independently of TBK1.
TBK1 Is Dispensable for NF-kB Activation Downstream
of STING
As we noted above, BMDMs generated from Tbk1fl/fl 3 Rosa-
Cre+ mice treated with tamoxifen retained a small amount of
detectable TBK1 protein (Figures 1A and S1A). We therefore
used CRISPR/Cas9 gene editing to generate TBK1-deficient
immortalized BMDMs (iBMDMs) by targeting exon 4 of the
Tbk1 gene locus with doxycycline-inducible single guide RNAs
(sgRNAs) (Figure S2A). To ensure our results were not affected
by residual TBK1 levels in the pool of CRISPR-targeted cells,
we generated single-cell clones deficient for TBK1 from the
polyclonal population. We hypothesized that if TBK1 is required
for both IRF3 and NF-kB activation, macrophages lacking TBK1
would phenocopy Sting–/– cells. We examined STING signaling
in response to DMXAA or 2030-cGAMP stimulation in WT,
TBK1KO, and Sting–/– iBMDMs by immunoblotting. As expected,
TBK1 deletion prevented phosphorylation of IRF3 (Figures 3A
and 3B). Consistent with previous reports, phosphorylation of
STING at S365 (S366 in humans) was also significantly reduced
in cells lacking TBK1 (Liu et al., 2015), but not ablated (Figures 3A
and 3B). In comparison, NF-kB p65 activation was relatively
normal, albeit with slightly delayed kinetics, following STING
activation in TBK1KO iBMDMs (Figures 3A and 3B). Not surpris-
ingly, activation of both IRF3 and NF-kB was absent in Sting–/–
iBMDMs. We observed consistent results from human TBK1KO
THP-1 monocytic cells following activation of STING with the
modified CDN, 2030-cyclic di-AMP (CDA) (PS)2 (RR), which also
retained p-p65 despite TBK1 deficiency (Figure S2B). We further
activated STING in WT, TBK1KO, and Sting–/– iBMDMs, and
examined cytokine secretion, observing a complete loss of
IFNb production in the absence of TBK1 or STING (Figure 3C).
In stark contrast, secretion of TNF was normal in the TBK1KO
cells, whereas Sting–/– iBMDMs remained unresponsive (Fig-
ure 3D). These results were consistent when we compared cyto-
kine responses across several TBK1-deficient iBMDM popula-
tions we generated via CRISPR (Figures S2C and S2D).
Furthermore, the kinetics of NF-kB-dependent cytokines, TNF,
IL-1b, and IL-12p40, appeared similar up to 8 h after STING acti-
vation between WT and TBK1-deficient macrophages (Figures
S2E–S2J). These data clearly demonstrate that STING-mediated
NF-kB signaling and cytokine responses are not lost in the
absence of TBK1 expression.
To assess STING activation in a disease-relevant, ligand-free
system, we next developed an in vitro model of the autoinflam-
matory disease SAVI that is caused by autoactivating mutations
in the gene encoding human STING, TMEM173 (Liu et al.,
2014). We modeled a form of SAVI caused by an arginine-to-
serine substitution at position 284 (R284S) of STING that we
and others recently described (Konno et al., 2018; Saldanha
et al., 2018). We used a doxycycline-inducible lentiviral system
allowing controlled expression of WT STING, STING R284S, or
an empty vector (EV) Ctrl on WT and TBK1-deficient genetic
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Figure 1. Primary TBK1-Deficient BMDMs Have
Normal STING-NF-kB Responses
(A) Primary BMDMs from tamoxifen-treated Tbk1fl/fl (WT) and
Tbk1fl/fl 3 RosaCre (TBK1 KO) mice were left untreated (UT)
or stimulated with 10 mg/mL 2’3’-cGAMP in digitonin reagent
(Dt) or Dt alone for 2 h, before cells were lysed for immuno-
blotting with the indicated antibodies. Data from three mice
of each genotype are shown as representative of two inde-
pendent experiments.
(B and C) Primary BMDMs from tamoxifen-treated Tbk1fl/fl
(WT) andTbk1 fl/fl 3 RosaCre (TBK1 KO) mice left untreated
(UT) or stimulated as indicated for 6 h before cell superna-
tants were collected to measure levels of secreted IFNb (B)
and TNF (C) by ELISA. Data represent the mean from three
combined experiments + SEM. *p < 0.05, **p < 0.01, ***p <
0.001, not significant (ns) comparing Tbk1fl/fl (WT) versus
Tbk1fl/fl 3 RosaCre (TBK1 KO) BMDMs as determined by
unpaired Student’s t test.
See also Figure S1.
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backgrounds. Overexpression of WT STING did not lead to au-
toactivation of downstream signaling in either WT or TBK1KO
iBMDMs (Figure 3E). On the other hand, expression of STING
R284S induced a strong signaling response in WT iBMDMs,
whereas iBMDMs lacking TBK1 showed negligible p-IRF3 but
maintained normal activation of NF-kB p65 (Figure 3E). In line
with these findings, IFNb, but not TNF secretion, was ablated
in the absence of TBK1 after STING R284S induction by doxy-
cycline (Figures 3F and 3G). These data further indicate that
TBK1 is expendable for NF-kB responses downstream of
STING activation.
TBK1 and IKKε Act Redundantly to Elicit STING-Induced
NF-kB Activation
Having demonstrated that TBK1 is dispensable for NF-kB activa-
tion downstream of STING, wewanted to examine a possible role
for the TBK1 homolog, IKKε, in this response. To this end, we
further generated IKKεKO and TBK1KO/IKKεKO iBMDMs using
CRISPR/Cas9 and tested their ability to elicit signaling in response
to STING activation. Consistent with our previous data, while p-
IRF3 was lost and p-STING was significantly reduced in TBK1KO
cells, NF-kB p-p65 was maintained with slightly delayed kinetics
(Figure 4A). In contrast with TBK1KO macrophages, IKKεKO
iBMDMs showed only minor impairment in their ability to induce
phosphorylation of both IRF3 and STING (Figure 4A). Similar to
loss of TBK1, cells lacking IKKε retained relatively normal phos-
phorylation of NF-kB p65, albeit slightly reduced at later time
points, following STING activation (Figure 4A). Most notably, how-
ever, TBK1KO/IKKεKO iBMDMs were completely unresponsive
upon STING activation, showing no detectable phosphorylation
of STING and IRF3, and only basal levels of NF-kB p65 activity
(Figure 4A). In line with our signaling data, TBK1KO and TBK1KO/
IKKεKO iBMDMs were unable to produce IFNb, whereas WT and
IKKεKO macrophages secreted similar amounts in response to
both DMXAA and 2030-cGAMP (Figures 4C and 4E). Meanwhile,
production of TNF was normal in TBK1KO and IKKεKO iBMDMs
(Figures 4D and 4F). Significantly, macrophages lacking both
TBK1 and IKKε were unable to secrete TNF in response to STING
activation (Figures 4D and 4F). Consistent with previous reports
(Hemmi et al., 2004; Perry et al., 2004), we found that loss of
TBK1, IKKε, or both TBK1 and IKKε had no effect on lipopolysac-
charide (LPS)-induced activation of NF-kB p65 or subsequent
TNF production (Figures 4B and 4D). Together, these data
demonstrate that TBK1 and IKKε can act redundantly in order to
activate STING-NF-kB responses, a mechanism that is distinct
from their role in TLR4 signaling.
STING-Induced NF-kB Responses Are Less Sensitive to
TBK1 and IKKε Kinase Inhibition Than Type I IFNs
Having established that TBK1 and IKKε act redundantly to drive
STING-NF-kB, we next assessed the effects of inhibiting their ki-
nase activity on STING responses. To do this, we pre-treated
primary BMDMswith the semi-selective TBK1/IKKε kinase inhib-
itors, WEHI-112 (Louis et al., 2019) or MRT67307, using DMSO
as a vehicle Ctrl, 1 h prior to STING activation. As previously re-
ported, we observed paradoxical autophosphorylation of TBK1
in the presence of WEHI-112 and MRT67307 (Louis et al.,
2019), but a loss of DMXAA-induced p-IRF3 (Figure S3A). Inter-
estingly, in the presence of TBK1/IKKε kinase inhibition, we still
observed increased p-p65 levels, although reduced relative to
Ctrl-treated BMDMs (Figure S3A). Similar results were seen
fromBMDMsactivatedwith the TLR3 ligand polyinosinic:polycy-
tidylic acid (polyI:C) followingWEHI-112 or MRT67307 pre-treat-
ment (Figure S3A). We next examined STING-induced signaling
Figure 2. TBK1-Deficient Mice Challenged with DMXAA Have No
Defects in NF-kB-Mediated Cytokine Expression
(A–H) Tamoxifen-treated Tbk1 fl/fl (WT) and Tbk1 fl/fl 3 RosaCre (TBK1 KO)
mice received intraperitoneal injection of either a DMSO control (Ctrl) or
500 mg (~20 mg/kg) DMXAA for 2 h. Mice were sacrificed before RNA was
isolated from splenic tissue, and type I IFN genes, Ifna1 (A), Ifna4 (B), Isg15
(C), and Ifnb1 (D), and NF-kB-dependent cytokine genes, Il1b (E), Il6 (F), Ccl4
(G), and Tnf (H), were measured by qPCR. Data represent the mean com-
bined for 4–6 mice per group ± SEM. **p < 0.01, not significant (ns)
comparing Tbk1 fl/fl (WT) versus Tbk1 fl/fl 3 RosaCre (TBK1 KO) mice in the
DMXAA-treated groups as determined by Mann-Whitney test.
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Figure 3. TBK1 Is Dispensable for NF-kB Activation Downstream of STING
(A and B)WT, TBK1KO, and Sting–/– iBMDMswere left untreated (0) or stimulated with 50 mg/mL DMXAA (A) or 10 mg/mL 2030-cGAMP in digitonin reagent (Dt) or Dt
alone (B) as shown, before cells were lysed for immunoblotting with the indicated antibodies. Data are representative of at least three independent experiments.
(C and D) WT, TBK1KO, and Sting–/– iBMDMs were left untreated (UT) or stimulated with 50 mg/mL DMXAA or 10 mg/mL 2030-cGAMP in lipofectamine (LF) or LF
alone for 6 h before cell supernatants were collected to measure levels of secreted IFNb (C) and TNF (D) by ELISA. Data represent the mean from three combined
experiments + SEM. *p < 0.05, ***p < 0.001, not significant (ns) compared with WT cells as determined by unpaired Student’s t test.
(legend continued on next page)
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kinetics (up to 3 h) following WEHI-112 pre-treatment at two
doses. In the presence of WEHI-112, we observed a substantial
dose-dependent reduction in p-IRF3 following STING activation
(Figures 5A and 5B). Conversely, robust STING-induced NF-kB
activation, indicated by increased p-p65 and reduced IkBa,
was maintained over time in the presence of WEHI-112, albeit
with slightly delayed kinetics (Figures 5A and 5B).
To examine the role of IKKε kinase activity in the complete
absence of TBK1, we next performed experiments where we
treated TBK1KO iBMDMs with WEHI-112. In TBK1KO iBMDMs,
IKKε was activated (p-IKKε), which was also observed in the
presence of WEHI-112 (Figures S3B and S3C), as previously
reported (Louis et al., 2019). In WEHI-112 pre-treated cells,
no differences were seen in the level of p-p65 in response to
either DMXAA or 2030-cGAMP (Figures S3B and S3C). Consis-
tent with this, TNF expression was similar between Ctrl and
WEHI-112-treated TBK1KO cells upon STING activation (Fig-
ure S3D). We then used immunofluorescence to monitor the
nuclear translocation of IRF3 and NF-kB p65 in response to
2030-cGAMP stimulation in the presence or absence of
WEHI-112 (Figures 5C and 5D). Quantification of the nuclear
intensity of IRF3 revealed a significant reduction in transloca-
tion between Ctrl and WEHI-112-treated cells, whereas NF-kB
p65 showed no difference (Figure 5E), indicating NF-kB nu-
clear translocation was not perturbed. In line with defective
IRF3 nuclear translocation upon STING activation, we
observed significantly blunted Ifnb1 expression and IFNb
secretion in the presence of WEHI-112 in DMXAA-treated cells
(Figures 5F and 5G). Meanwhile, NF-kB-dependent TNF levels
were less sensitive to WEHI-112 treatment, showing only mi-
nor reductions (Figures 5H and 5I). Similar results were seen
when BMDMs were stimulated with 2030-cGAMP or infected
with HSV-1 following WEHI-112 pre-treatment, compared
with Ctrl (Figures 5J–5M). Of note, HSV-1-induced IFNb and
TNF responses were entirely dependent on STING expression
in this experimental system (Figures S4A and S4B). Consis-
tently, comparable observations using the TBK1/IKKε inhibi-
tor, BX-795, prior to STING activation with bacterial CDNs
were reported by Blaauboer et al. (2014).
Gram-positive bacterial species Listeria monocytogenes is
known to induce a STING-dependent type I IFN response driven
through the recognition of both bacterial DNA and CDNs by
cGAS and STING, respectively (Marinho et al., 2017). Therefore,
we next examined NF-kB responses downstream of Listeria
monocytogenes infection in BMDMs from Tmem173+/+ (referred
to here as Sting+/+) and Sting–/– mice. Both Sting+/+ and Sting–/–
exhibited a robust increase in p-p65 at the signaling level, as well
as normal Tnf expression, in the presence ofWEHI-112 upon Lis-
teria infection (Figures S4C and S4D), demonstrating that under
these experimental conditions, NF-kB activation occurs inde-
pendently of STING. Comparatively, the expression of Ifnb1
was highly dependent on STING expression and, similar to our
previous findings, was substantially reduced in the presence of
WEHI-112 (Figure S4E).
Because TBK1 and IKKε kinase inhibition was critical for type I
IFN production but dispensable for cGAS-STING-induced NF-kB
activation in mouse macrophages, we also wanted to determine
whether the same was true of human immune cells. To do this,
we isolated peripheral blood mononuclear cells (PBMCs) from
healthy human donors and pre-treated them with WEHI-112
before stimulating cells with the cyclic-di-AMP analog, 2030-CDA
(PS)2 (RR), or with transfected HT-DNA. Consistent with our re-
sults frommousemacrophages, comparedwithCtrl, weobserved
a dose-dependent reduction in STING-induced IFNB1 expression
uponWEHI-112 treatment (Figure 5N). In contrast, there was little
difference in TNF expression with WEHI-112 pre-treatment upon
STING activation (Figure 5O). We then used our doxycycline-
inducible lentiviral system to express WT STING, STING R284S,
or an EV Ctrl in human THP-1 monocytes. As in WT iBMDMs,
overexpression of WT STING failed to induce phosphorylation of
STING, or any downstream signaling components, whereas
expression of STING R284S led to robust phosphorylation of
STING, TBK1, IRF3, and NF-kB p65 (Figure 5P). In addition, only
expression of STINGR284S resulted in significant downstream in-
duction of IFNB1, IRF7, TNF, and IL1B inflammatory genes (Fig-
ures S4F–S4I). Importantly, pre-treatment of these THP-1 mono-
cytes with two different doses of WEHI-112 prior to
doxycycline-induced STING R284S expression markedly
decreased IFNB1 expression in a dose-dependent manner (Fig-
ure 5Q). Conversely, there was no change in TNF expression be-
tween vehicle Ctrl or WEHI-112-treated THP-1 monocytes ex-
pressing STING R284S (Figure 5R).
Taken together, these data strongly suggest that downstream
of cGAS-STING, the activation of IRF3 and subsequent produc-
tion of IFNb are exquisitely reliant on the kinase activities of
TBK1 and IKKε, whereas NF-kB-dependent cytokine responses
are less so.
TAK1 and IKKb, but Not TRAF6, Are Required for STING-
NF-kB Responses
The E3 ubiquitin (Ub) ligase TNF receptor-associated factor 6
(TRAF6) is well known to drive NF-kB downstream of TLR activa-
tion (Balka and De Nardo, 2019) and has also been implicated in
both canonical and non-canonical STING-mediated activation
of NF-kB in response to dsDNA and nuclear DNA damage,
respectively (Abe and Barber, 2014; Dunphy et al., 2018). In
fact, recently, STING-mediated NF-kB responses in zebrafish,
but not humans, were shown to be enhanced via interactions
with TRAF6 (de Oliveira Mann et al., 2019). Hence we generated
iBMDMs deficient in TRAF6 (TRAF6KO) and tested their ability to
activate NF-kB in response to STING activation. Both DMXAA-
and 2030-cGAMP-induced STING signaling, including increased
(E) WT and TBK1KO iBMDMs stably transduced with either an empty vector (EV) Ctrl, WT STING, or STING R284S were left untreated (0) or treated with 1 mg/mL
doxycycline for 3 and 6 h in order to induce protein expression. Cells were then lysed for immunoblotting with the indicated antibodies. Data are representative of
three independent experiments.
(F and G) Cell supernatants were collected after 6 h of 1 mg/mL doxycycline tomeasure levels of secreted IFNb (F) and TNF (G) by ELISA. Data represent the mean
from three combined experiments + SEM. *p < 0.05, not significant (ns) compared with WT iBMDMs as determined by unpaired Student’s t test.
See also Figure S2.
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p-p65 and loss of IkBa, were equivalent in bothWT and TRAF6KO
iBMDMs, whereas in contrast, TLR9 (CpG DNA)-dependent
NF-kB responses were ablated in TRAF6-deficient macro-
phages (Figures 6A and 6B). Consistently, secretion of TNF
following DMXAA or 2030-cGAMP stimulation was also similar in
WT and TRAF6KO iBMDMs (Figure 6C). In contrast, but as ex-
pected, TNF production was completely lost in cells lacking
TRAF6 in response to TLR9 or TLR2 (P3C) activation (Figure 6C).
These findings demonstrate that although TRAF6 is critically
required for TLR responses, it is not required for canonical
NF-kB activation during STING signaling.
In order to investigate further how NF-kB is activated down-
stream of STING activation, we examined the role of putative up-
stream transforming growth factor b-activated kinase 1 (TAK1)
and the IKK signaling complexes via pharmacological inhibition.
We pre-treated BMDMs with a vehicle Ctrl (DMSO), an IKKb ki-
nase inhibitor (TPCA-1), or a TAK1 kinase inhibitor (5z-7-Oxo-
zeaenol) before stimulating cells with either DMXAA or 2030-
cGAMP (Figures 6D and 6E). Inhibition of IKKb or TAK1 kinase
activity significantly reduced levels of p-p65 and the loss of
IkBa (Figures 6D and 6E). In contrast, p-STING and p-TBK1
were only minimally affected by IKKb kinase inhibition, although
p-IRF3 was reduced, as previously reported in cells depleted of
IKKb (Fang et al., 2017). We also noted that TAK1 kinase inhibi-
tionmodestly reduced p-STING, p-IRF3, and p-TBK1 levels (Fig-
ures 6D and 6E). However, these differences are unlikely to
Figure 4. STING Activates NF-kB in a TBK1/IKKε Redundant Manner
(A and B) WT, TBK1KO, IKKεKO, and TBK1KO/IKKεKO iBMDMs were left untreated (0) or stimulated with 50 mg/mL DMXAA (A) or 200 ng/mL LPS (B) as shown,
before cells were lysed for immunoblotting with the indicated antibodies. Data are representative of three independent experiments.
(C–F) WT, TBK1KO, IKKεKO, and TBK1KO/IKKεKO iBMDMs were left untreated (UT) or stimulated with 50 mg/mL DMXAA, 200 ng/mL LPS (C and D), or 10 mg/mL
2030-cGAMP in lipofectamine (LF) or LF alone (E and F) for 6 h before cell supernatants were collected tomeasure levels of secreted IFNb (C and E) and TNF (D and
F) by ELISA. Data represent themean from three combined experiments + SEM. *p < 0.05, **p < 0.01, not significant (ns) comparedwithWT cells as determined by
unpaired Student’s t test.
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account for the reductions observed in STING-induced p-p65
following TAK1 inhibition. These data strongly suggest that the
IKKb and TAK1 complexes are activated downstream of
STING-induced TBK1 and IKKε activity. Of note, TAK1 kinase in-
hibition strongly inhibited STING-dependent phosphorylation of
IKKa and IKKb, further suggesting that TAK1 acts upstream of
the IKK complex (Figures 6D and 6E). Similar results were ob-
tained following stimulation of TLR9 with CpG DNA, which is
known to activate IKKb- and TAK1-dependent NF-kB activation.
Together, these data demonstrate that STING activation elicits
the kinase activities of both TAK1 and IKKb to drive subsequent
NF-kB responses.
DISCUSSION
The cGAS-STING pathway comprises a major component of the
host innate immune response to viral infection. Beyond this, it
has also been implicated as a key player in a number of cellular
and disease processes, including autoimmune disease, autoin-
flammatory conditions, neurodegenerative disorders, and can-
cer. Due to the robust nature of the type I IFN response elicited
via cGAS-STING, enormous focus has been placed on the
mechanisms underpinning this process. However, although
less studied, the NF-kB pathway is also of great importance to
STING responses. It is a widely held view that TBK1 alone elicits
NF-kB responses downstream of STING, but we now provide
evidence that redefines the fundamental molecular mechanisms
of STING-induced NF-kB signaling (Figure S5). We demonstrate
that, in fact, TBK1 and IKKε act redundantly to drive NF-kB acti-
vation, whereas type I IFN responses are elicited by TBK1 and its
kinase activity. We further demonstrate that phosphorylation of
STING at serine 365 (366 in humans) is predominantly mediated
by kinase activity of TBK1; however, residual phosphorylation at
this site occurs in the absence of TBK1, through IKKε. In
contrast, activation of STING-induced NF-kB activation appears
significantly less dependent on the kinase activities of TBK1 and
IKKε. Of note, the TBK1/IKKε redundant mechanism appears
specific to STING-mediated NF-kB signaling, as we (Figure 4)
and others have shown that TLRs, as well as IL-1b and TNF
signaling, drive NF-kB responses in a TBK1- and IKKε-indepen-
dent manner (Clark et al., 2009; Hemmi et al., 2004; Perry et al.,
2004). Downstream of STING and TBK1/IKKε, we further show
that the TAK1 and IKK complexes drive canonical NF-kB re-
sponses and the production of pro-inflammatory cytokines
(Figure 6 and Figure S5).
Our revised model of STING signaling has important implica-
tions regarding the clinical efficacy of therapies targeting
STING-related responses. To date, suggested therapies for
numerous autoimmune and autoinflammatory diseases, espe-
cially in the group of type I interferonopathies, has involved tar-
geting IFN pathways. TBK1 has been postulated as a potential
therapeutic target for treating such diseases (Hasan and Yan,
2016). Our findings demonstrate that TBK1 kinase inhibition
may not lead to complete control of STING-driven pathology
and broader type I interferonopathies. However, TBK1/IKKε in-
hibitors may still provide health benefits for a number of diseases
related to STING activation, including TREX1-mediated autoim-
munity (Hasan et al., 2015). For example, the cGAS-STING
pathway is heavily implicated in the development of autoimmu-
nity (e.g., Aicardi-Goutie`res syndrome and forms of lupus) in hu-
mans and mice lacking the DNA degrading exonuclease DNase
III (also known as TREX1). Indeed, the pathology of Trex1–/–mice
is completely rescued by crossing these animals to either IFNAR
(the receptor for type I IFNs)- or STING-deficient mice (Gall et al.,
Figure 5. STING-Induced NF-kB Activity Is Less Sensitive to TBK1/IKKε Kinase Inhibition Than Type I IFN Responses
(A and B) Primary BMDMs were pre-treated with either a DMSO vehicle Ctrl or 50 and 200 nMWEHI-112 (TBK1/IKKε kinase inhibitor) for 1 h prior to stimulation
with 50 mg/mLDMXAA (A) or 10 mg/mL 2030-cGAMP in digitonin reagent (Dt) or Dt alone (B) as shown, before cells were lysed for immunoblotting with the indicated
antibodies. Data are representative of at least three independent experiments.
(C–E) Primary BMDMs were pre-treated with either a DMSO vehicle Ctrl or 200 nMWEHI-112 for 1 h and then stimulated with 10 mg/mL 2030-cGAMP in digitonin
reagent (Dt) or Dt alone for 4 h before fixation and staining for IRF3 (C) or NF-kB p65 (D) and nuclei (shown in blue). Samples were then examined by confocal
microscopy. Representative images are presented from four biological replicates (C and D). Scale bars, 10 mm. (E) IRF3 and NF-kB p65 nuclear translocation was
then quantified by examining the mean fluorescence intensity. Data represent the mean from four biological replicates ± SEM. *p < 0.05, not significant (ns)
compared with Ctrl as determined by unpaired Student’s t test.
(F–I) Primary BMDMs were pre-treated with either a DMSO vehicle Ctrl or 50 nMWEHI-112 for 1 h prior and then left untreated (UT) or stimulated with 50 mg/mL
DMXAA for 4 h before cells were lysed for RNA isolation and Ifnb1 (F) and Tnf (H) gene expression analysis by qPCR, and cell supernatants were collected to
measure levels of secreted IFNb (G) and TNF (I) by ELISA. Data represent the mean from three combined experiments + SEM. *p < 0.05, **p < 0.01, ***p < 0.001,
not significant (ns) compared with Ctrl as determined by unpaired Student’s t test.
(J–M) Primary BMDMswere pre-treatedwith either a DMSO vehicle Ctrl or 50 nMWEHI-112 for 1 h prior and then left untreated (UT/0) or stimulatedwith 10 mg/mL
2030-cGAMP in lipofectamine (LF) or LF alone (J and K), or infected with HSV-1 as indicated (L and M) for 4 h, before cell supernatants were collected to measure
levels of secreted IFNb (J and L) and TNF (K and M) by ELISA. Data represent the mean from three combined experiments + SEM. *p < 0.05, **p < 0.01, not
significant (ns) compared with Ctrl as determined by unpaired Student’s t test.
(N and O) Fresh human peripheral bloodmononuclear cells (PBMCs) were pre-treated with either a DMSO vehicle Ctrl, 50 nMWEHI-112, or 200 nMWEHI-112 for
1 h and then left untreated (UT) or stimulated with 20 mM 2030-cyclic di-AMP (CDA) (PS)2 (RR) added directly to the media, HT-DNA in lipofectamine (LF), or LF
alone for 16 h before analysis of IFNB1 (N) and TNF (O) gene expression by qPCR. Data represent the mean of five combined human donor samples ± SEM. *p <
0.05, not significant (ns) compared with Ctrl as determined by paired Student’s t test.
(P) THP-1 monocytic-like cells stably transduced with either an empty vector (EV) Ctrl, WT STING, or STING R284S were left untreated (–) or treated with 1 mg/mL
doxycycline for 3 h (+) in order to induce protein expression. Cells were then lysed for immunoblotting with the indicated antibodies. Data are representative of
three independent experiments.
(Q and R) THP-1monocytic cells stably transducedwith either an empty vector (EV) Ctrl, WT STING, or STING R284S were pre-treated with 50 or 200 nMWEHI-112
before treatment with 1 mg/mL doxycycline for 6 h. Cells were lysed, and RNAwas isolated before analysis of IFNB1 (Q) and TNF (R) gene expression by qPCR. Data
represent the mean from three combined experiments + SEM. *p < 0.05, not significant (ns) compared with Ctrl as determined by unpaired Student’s t test.
See also Figures S3 and S4.
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2012; Stetson et al., 2008). Furthermore, targeted TBK1/IKKε in-
hibition could be beneficial against certain bacterial infections
that create a protective niche by exploiting STING-mediated
type I IFNs, such as Listeria monocytogenes (Marinho et al.,
2017). In this context, TBK1/IKKε inhibitors would effectively
reduce type I IFNs, thereby redirecting the host’s cellular
response to a primarily NF-kB-driven, anti-bacterial inflamma-
tory state.
Diseases driven by aberrant cGAS-STING activation can
display pathologies independent of type I IFNs. For instance,
DNaseII-mediated autoimmunity that manifests as chronic
polyarthritis is driven by a strong pro-inflammatory cytokine
response that can be rescued by crossing DnaseII–/– mice to
those lacking cGAS or STING (Ahn et al., 2012; Gao et al.,
2015), but not IFNAR (Kawane et al., 2006, 2010). Likewise,
murine models of SAVI have demonstrated potentially signifi-
cant roles for non-IFN signaling downstream of STING autoac-
tivation. Namely, when STING gain-of-function mice were
crossed onto an Irf3–/– background, animals retained perivas-
cular pulmonary inflammation, myeloid cell expansion, and
T cell cytopenia, suggesting that other STING-induced path-
ways may play a key role in disease pathogenesis (Warner
et al., 2017). In line with this finding, several recent studies
observed that when STING N153S or V154M gain-of-function
mice were crossed to IRF3- or IFNAR-deficient mice, the SAVI
phenotype (e.g., lung disease) ensued independently of the
type I IFN pathway (Luksch et al., 2019; Motwani et al.,
2019). Moreover, IFNAR-deficient STING gain-of-function
mice were actually found to exhibit significant lung and kidney
inflammation (Bouis et al., 2019). In the context of SAVI pa-
tients, targeting the signaling pathway downstream of IFNAR
via JAK inhibition has shown the greatest efficacy; however,
in some reported cases, significant disease-associated
pathologies have persisted in spite of treatment (Saldanha
et al., 2018; Sanchez et al., 2018). Ultimately, this suggests
the clinical scope of TBK1/IKKε kinase inhibition in cGAS-
STING pathology needs to be carefully considered. In this re-
gard, the recent development of small-molecule compounds
directly inhibiting cGAS or STING may have greater potential
for clinical translation. Indeed, administration of specific
cGAS and STING antagonists was recently shown to signifi-
cantly diminish inflammation and disease pathologies in the
Trex1–/– mouse model (An et al., 2018; Haag et al., 2018). It
would be of great interest to evaluate the efficacy of such
compounds in SAVI mice and other disease models that
display non-IFN-dependent pathologies.
STING agonists have also emerged as a major therapeutic
target for cancer immunotherapy, with several molecules
currently in phase I clinical trials (Zhu and Li, 2018). It is well
known that endogenous type I IFNs are beneficial in limiting
cancer progression by priming T cells and driving anti-cancer
immune responses (Zitvogel et al., 2015). For instance, IFNAR
signaling has been shown to be critical for STING-mediated tu-
mor suppression in murinemodels of melanoma (Corrales et al.,
2015; Demaria et al., 2015). However, the role of STING-
induced NF-kB in cancer is not well defined. Of potential
benefit, NF-kB can synergize with IRF3 to increase maximal
expression of IFNb. On the other hand, it is well described
that NF-kB can be constitutively activated in cancer cells
driving tumor initiation and metastasis, as well as promoting
cell survival and proliferation (Taniguchi and Karin, 2018).
Hence a number of anti-cancer agents target components of
NF-kB signaling (Baud and Karin, 2009). The ability of STING
to activate NF-kB may therefore diminish the full potential of
STING agonists for anti-cancer therapy. As such, STING activa-
tion in combination with reduced NF-kB activity could provide
synergistic benefit for tumor immunotherapy. Therefore,
studies more closely examining the role of STING-induced
NF-kB in murine models of cancer would also be of great
interest.
In summary, our work identifies the molecular mechanisms
underpinning NF-kB activation by STING, distinguishing this
pathway from IRF3-mediated type I IFN responses. These find-
ings prompt future research questions regarding the regulation
of signaling events downstream of STING and have further impli-
cations regarding therapeutic targeting of STING-related dis-
eases and cancer immunotherapy.
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Lipofectamine 2000 Transfection Reagent Thermo Fisher Scientific Cat# 11668030
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MRT67307 (TBK1/IKKε kinase inhibitor) Sigma-Aldrich Cat# SML0702
TPCA-1 (IKKb kinase inhibitor) Sigma-Aldrich Cat# T1452
5z-7-Oxozeaenol (TAK1 kinase inhibitor) Sigma-Aldrich Cat# O9890
WEHI-112 (TBK1/IKKε kinase inhibitor) Walter and Eliza Hall Institute
of Medical Research
(Louis et al., 2019)
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NuPAGE 4-12% Bis-Tris Protein Gels, 1.5 mm, 10-well Thermo Fisher Scientific Cat# NP0335BOX
NuPAGE 4-12% Bis-Tris Protein Gels, 1.5 mm, 15-well Thermo Fisher Scientific Cat# NP0336BOX
NuPAGE 4-12% Bis-Tris Midi Protein Gels, 20-well Thermo Fisher Scientific Cat# WG1402A
NuPAGE MES SDS Running Buffer (20X) Thermo Fisher Scientific Cat# NP000202
Immobilon-P PVDF Membrane, 0.45 mm pore size,
Hydrophobic PVDF
Merck Millipore Cat# IPVH00005
cOmplete Protease Inhibitor Cocktail Roche Biochemicals Cat# 11836145001
Immobilon Forte Western HRP substrate Merck Millipore Cat# WBLUF0500
TNF alpha Mouse Uncoated ELISA Kit Thermo Fisher Scientific Cat# 88-7324-88
Nunc MaxiSorp flat-bottom ELISA plates Thermo Fisher Scientific Cat# 442404
m–Slide 8 well Ibidi Cat# 80826
QuikChange Lightning Mutagenesis Kit Agilent Technologies Cat# 210513
Experimental Models: Cell Lines
Human embryonic kidney (HEK) 293T cells ATCC CRL-3216
WT immortalized bone marrow-derived macrophages
(iBMDMs)
Eicke Latz Laboratory N/A
WT immortalized bone marrow-derived macrophages
(iBMDMs) expressing Cas9-mCherry
This paper N/A
WT immortalized bone marrow-derived macrophages
(iBMDMs) expressing pTRIPZ empty vector (EV)
This paper N/A
WT immortalized bone marrow-derived macrophages
(iBMDMs) expressing WT hsSTING
This paper N/A
WT immortalized bone marrow-derived macrophages
(iBMDMs) expressing hsSTING R284S
This paper N/A
TBK1KO immortalized bone marrow-derived
macrophages (iBMDMs)
This paper N/A
TBK1KO immortalized bone marrow-derived
macrophages (iBMDMs) expressing pTRIPZ
empty vector (EV)
This paper N/A
TBK1KO immortalized bone marrow-derived
macrophages (iBMDMs) expressing WT hsSTING
This paper N/A
TBK1KO immortalized bone marrow-derived
macrophages (iBMDMs) expressing hsSTING R284S
This paper N/A
TRAF6KO immortalized bone marrow-derived
macrophages (iBMDMs)
This paper N/A
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IKKεKO immortalized bone marrow-derived
macrophages (iBMDMs)
This paper N/A
TBK1KO/IKKεKO immortalized bone marrow-derived
macrophages (iBMDMs)
This paper N/A
Sting–/– immortalized bone marrow-derived
macrophages (iBMDMs)
This paper N/A
WT THP-1 human monocytic cells ATCC TIB-202
WT THP-1 human monocytic cells expressing
Cas9-mCherry
This paper N/A
THP-1 TBK1KO human monocytic cells Ian Wicks Laboratory (Louis et al., 2019)
THP-1 human monocytic cells expressing pTRIPZ
empty vector (EV)
This paper N/A
THP-1 human monocytic cells expressing WT
human STING
This paper N/A




Tbk1fl/fl (C56BL/6J-Tbk1tm1.1 mrl) mice Taconic Model# 11131
Tbk1fl/fl x RosaCre+ (C56BL/6J) mice This paper N/A
C57BL/6J mice (for bone marrow-derived
macrophages- BMDMs)
Jackson Laboratory Cat# 000664
Sting–/– mice (for bone marrow-derived
macrophages- BMDMs)
Benjamin Kile Laboratory N/A
Sting+/+ mice (for bone marrow-derived
macrophages- BMDMs)
Benjamin Kile Laboratory N/A
Oligonucleotides
Tbk1 targeting sgRNA This paper GAGGAGCCGTCCAATGCGTA
Ikbke targeting sgRNA This paper TGTCCAGCGACACACCTAAG
Traf6 targeting sgRNA This paper ATCCCGGGGATGTCGTCCAG
hsSTING DAgeI mutagenesis primer This paper CCCCAGCAGACAGGTGACCAT
GCTGGC
hsSTING DAgeI PCR amplification forward primer This paper GCACCGGTATGCCCCACTCCAGCCTG
hsSTING DAgeI PCR amplification reverse primer This paper GCACGCGTTCAAGAGAAATCCGT
GCGGAG
hsSTING R284S mutagenesis primer This paper GGCTTTAGCCGGGAGGATAGCCTTG
AGCAGGCC
qPCR primer sequences
Mouse Hprt forward This paper TGAAGTACTCATTATAGTCAAGGGCA
Mouse Hprt reverse This paper CTGGTGAAAAGGACCTCTCG
Mouse Ifnb1 forward This paper CCAGCTCCAAGAAAGGACGA
Mouse Ifnb1 reverse This paper TGGATGGCAAAGGCAGTGTA
Mouse Ifna1 forward This paper CTACTGGCCAACCTGCTCTC
Mouse Ifna1 reverse This paper CCTTCTTGATCTGCTGGGCA
Mouse Ifna4 forward This paper CCTGTGTGATGCAGGAACC
Mouse Ifna4 reverse This paper TCACCTCCCAGGCACAGA
Mouse Il2b forward This paper GGAAGCACGGCAGCAGAATA
Mouse Il2b reverse This paper ACTTGAGGGAGAAGTAGGAATGG
Mouse Isg15 forward This paper TGTGAGAGCAAGCAGCCAGA
Mouse Isg15 reverse This paper cccccagcatcttcaccttt
Mouse Tnf forward This paper CCAAATGGCCTCCCTCTCAT
Mouse Tnf reverse This paper TGGTGGTTTGCTACGACGTG
Mouse Il1b forward This paper TTGACGGACCCCAAAAGATG
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LEAD CONTACT AND MATERIALS AVAILABILITY
All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer
Agreement. Further information and/or requests for resources and reagents should be directed to the Lead Contact, Dr Dominic
De Nardo (dominic.denardo@monash.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
C57BL/6 wild-type, Tbk1fl/fl (WT), Tbk1fl/fl xRosaCre (TBK1 KO), Sting+/+ and Sting–/–mice were housed under standard conditions at
the Walter and Eliza Hall Institute Animal Facility. All procedures involving mice were approved by the Walter and Eliza Hall
Institute Animal Ethics Committee. Male and female 8-week old Tbk1fl/fl (WT) and Tbk1fl/fl x RosaCre (TBK1 KO) mice received
3 mg tamoxifen by oral gavage per dosing for 4 consecutive days before intraperitoneal injection of either a DMSO control (Ctrl)
or 500 mg (20mg/kg) DMXAA diluted in 400 mL phosphate buffered saline (PBS) with 20%Captisol carrier solution. Mice were sacri-
ficed 2h later for harvesting spleens.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Mouse Il1b reverse This paper CAGCTTCTCCACAGCCACAA
Mouse Ccl4 forward This paper ACCTAACCCCGAGCAACACC
Mouse Ccl4 reverse This paper GAGCCCATTGGTGCTGAGAA
Mouse Il6 forward This paper CCAGAAACCGCTATGAAGTTCC
Mouse Il6 reverse This paper CGGACTTGTGAAGTAGGGAAGG
Human HPRT1 forward This paper TCAGGCAGTATAATCCAAAGATGGT
Human HPRT1 reverse This paper AGTCTGGCTTATA TCCAACACTTCG
Human ACTIN forward This paper GCGAGAAGATGACCCAGATC
Human ACTIN reverse This paper CCAGTGGTACGGCCAGAGG
Human IFNB1 forward This paper TGTCGCCTACTACCTGTTGTGC
Human IFNB1 reverse This paper AACTGCAACCTTTCGAAGCC
Human TNF forward This paper TCTCTCAGCTCCACGCCATT
Human TNF reverse This paper CCCAGGCAGTCAGATCATCTTC
Recombinant DNA
pEF-BOS-mCitrine-hsSTING Veit Hornung Laboratory N/A
pEF-BOS-mCitrine-hsSTING DAgeI This paper N/A
pTRIPZ Inducible Lentiviral Empty Vector (EV) Control Dharmacon Cat# RHS4750
pTRIPZ-hsSTING (DAgeI) This paper N/A
pTRIPZ-hsSTING (DAgeI) R284S This paper N/A
pMD2.G Addgene Plasmid #12259
psPAX2 Addgene Plasmid# 12260
FUCas9mCherry Addgene Plasmid# 70182
pFgH1tUT-GFP Addgene Plasmid# 70183
pFgH1tUT-HygroR This paper N/A
pFgH1tUT-GFP Tbk1 targeting sgRNA This paper N/A
pFgH1tUT- HygroR Ikbke targeting sgRNA This paper N/A
pFgH1tUT-GFP Traf6 targeting sgRNA This paper N/A
Software and Algorithms
FIJI https://fiji.sc RRID: SCR_002285
Image Lab Bio-Rad Laboratories RRID:SCR_014210
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Primary murine and human immune cells
Bone marrow cells were harvested from femurs and tibias of 6 to 8-week old male or female mice and cultured with complete Dul-
becco’s Modified Eagle Medium (DMEM, Thermo Scientific) [DMEM with 1% (w/v,) D-glucose, 0.11% (w/v) sodium pyruvate, 0.1%
(w/v) streptomycin, 100u/mL penicillin and 10% fetal bovine serum (FBS) (Sigma-Aldrich)] supplemented with 20% L929 conditioned
media for six days at 37C in humidified atmospherewith 5%CO2 to generate primary bonemarrow-derivedmacrophages (BMDMs).
Human peripheral blood mononuclear cells (PBMCs) were isolated from whole blood over a Ficoll density gradient (GE Healthcare)
with the approval of theWalter and Eliza Hall Institute Human Research Ethics Committee. Following several washes with phosphate
buffered saline (PBS) PBMCs were cultured in complete Roswell Park Memorial Institute media 1640 (RPMI-1640) [1% (w/v) RPMI-
1640, 0.2% (w/v) NaHCO3, 0.011% (w/v) C3H3NaO3, 0.1% (w/v) streptomycin, 100u/mL penicillin, supplemented with 10% FBS] at
37C in humidified atmosphere with 5% CO2.
Immortalized cell lines
Human Embryonic Kidney 293T (HEK293T) cells and iBMDMs were cultured in complete DMEM at 37C in 5% CO2 humidified at-
mosphere. THP-1 human monocyte-like cells were maintained in complete RPMI at 37C in humidified atmosphere with 5% CO2.
Sting–/– immortalized BMDMs (iBMDMs)
Sting–/– iBMDMs were generated as described (De Nardo et al., 2018b). Bone marrow cells from Sting–/– mice were harvested from
the femurs of an 8-week oldmalemouse and culturedwith complete DMEMsupplementedwith 20%L929 conditionedmedia for two
days. Cells were then subjected to J2 recombinant retrovirus (50%) in DMEMsupplemented with 20%L929 conditionedmedia for 24
h, before further culture in DMEM with 20% L929 conditioned media for 4 days to generate BMDMs. Cells were subsequently
cultured for 3 months with gradual reductions of L929 conditioned media until they were able to survive and proliferate in the
absence of any L929. At this point cells were considered immortalized and phenotypically and functionally tested in comparison
with primary BMDMs.
Gene knockout cells via CRISPR/Cas9
TBK1KO, IKKεKO, TBK1KO/IKKεKO and TRAF6 KO iBMDMs were generated by CRISPR/Cas9 gene editing as previously described
(Baker and Masters, 2018). Third generation lentiviral transduction was used to generate WT iBMDMs expressing Cas9 fused to
mCherry (using the FUCas9mCherry plasmid), which were subsequently enriched by FACS sorting. Doxycycline-inducible sgRNA
plasmids (using pFgH1tUT plamids) targeting specific genes of interest were then introduced into iBMDMs expressing Cas9-
mCherry via third generation lentiviral transduction (described below). Cells expressing sgRNA plasmids were then enriched by either
FACS or antibiotic selection. Gene disruption was confirmed by immunoblot analysis of target proteins and functional analysis. The
sgRNA targeting sequences used are provided in the Key Resources Table.
METHOD DETAILS
Generation of lentiviral plasmids
The second-generation pTRIPZ-hsSTING lentiviral plasmid expressing a doxycycline-inducible human STING, was generated by
amplifying STING DAgeI cDNA from a template plasmid (pEF-BOS-mCitrine-hsSTING DAgeI) before the resultant PCR product
was digested with AgeI andMluI and cloned in-frame into the corresponding sites of pTRIPZ. The pTRIPZ-hsSTING (DAgeI) plasmid
was then used to generate pTRIPZ-hSTING R284S (DAgeI) using the QuikChange Lightning Mutagenesis Kit (Agilent Technologies).
Third-generation sgRNA plasmids were generated by annealing specific sgRNA oligo sequences before ligation into BsmBI sites of
pFgH1tUT (GFP or HygroR). Plasmids were subsequently subjected to sanger sequencing (Australian Genome Research Facility
[AGRF] or Monash Micromon). All primer sequences used are listed in the Key Resources Table.
Lentiviral transduction
Lentiviral transduction of THP-1 human monocyte-like cells or iBMDMs was performed similarly to published viral transduction pro-
tocols (Cardona Gloria et al., 2018; Moghaddas et al., 2018). Third-generation lentivirus was generated by transient transfection of
HEK293T cells with lentiviral plasmids (FUCas9mCherry, pFgH1tUT), pMDL (packaging), RSV-REV (packaging) and VSVg (envelope)
plasmids complexed into liposomes using Lipofectamine 2000 (Thermo Scientific) diluted inOptimMEM (ThermoScientific). Second-
generation lentivirus was generated via transient transfection of HEK293T cells with lentiviral pTRIPZ, pPAX2 (packaging) and
pMD2.G (envelope) plasmids complexed into liposomes using Lipofectamine 2000 (Thermo Scientific) diluted in OptimMEM (Thermo
Scientific). Third- and second-generation lentiviruses were harvested 48 h later, filtered through 0.45 mm filters and used to infect
THP-1 or iBMDMs target cell lines. Cells were subsequently enriched for lentiviral plasmid expression via antibiotic selection or
FACS sorting.
Preparation of whole-cell lysates (WCLs)
For immunoblot assays, 1-1.5 3 106 THP-1 monocytes, iBMDMs or primary BMDMs were lysed on ice with 150 ml of 1 x Radio-
immune precipitation assay (RIPA) buffer [20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10% glycerol,
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0.1% SDS and 0.5% deoxycholate, 5mM NaF, 10mM NaPPi, 1mM Na3VO4] supplemented with 1mM phenylmethylsulfonyl fluoride
(PMSF) and 1 x cOmplete protease inhibitors (Roche Biochemicals). WCLs were clarified by centrifugation at 17,000 x g for 1 min
through Pierce centrifuge columns (Thermo Scientific) before 60 mL was diluted with 20 mL 4x reducing SDS-PAGE sample loading
buffer [1.25% SDS, 12.5% glycerol, 62.5 mM Tris-HCl pH 6.8, 0.005% bromophenol blue, 50 mM dithiothreitol] and heated to 95C
for 10 min.
Immunoblotting
Between 20-35 ml of prepared WCL samples were run on NuPAGE 4%–12% Bis-Tris Protein Gels (Thermo Scientific) with MES or
MOPS running buffer (Thermo Scientific). Following activation of Immobilon-P polyvinyl difluoride (PVDF) membrane (Millipore Merk)
in methanol, proteins were transferred to membranes using the Trans-Blot Turbo System (BioRad). Membranes were then blocked
using 5% skim milk powder in Tris buffered saline (TBS) + 0.1% Tween 20 (TBST) at room temperature (RT) for 1 h before incubation
overnight in primary antibodies at 4C. Membranes were then washed 3x in TBST (10-20 min per wash) and incubated with appro-
priate secondary antibodies for 1-2 h at RT before membranes were again washed 3x in TBST. Chemiluminescence was detected by
subjecting membranes to Immobilon Forte Western HRP substrate (Millipore Merk) before imaging using the ChemiDoc Touch or
ChemiDoc XRS+ Imaging Systems (BioRad). Images were acquired and converted to tagged image format file (TIFF) using Image
Lab software (BioRad). When required protein was removed from membranes using a mild stripping buffer [1.5% glycine, 1%
SDS, 0.01% Tween 20, pH 2.2] before 3x washes in TBST and re-probing with primary antibodies. Primary and secondary antibodies
used for immunoblot used are listed in the Key Resources Table.
Quantitative real time-PCR
RNA was purified from 1 3 106 THP-1 monocytes or iBMDMs, 1.2 3 106 BMDMs or 2.5 3 106 PBMCs using either the EZ-10
DNAaway RNAMiniprep Kit (Bio Basic), or > 30mg of splenic tissue using the ISOLATE II RNAmini kit (Bioline) according to theman-
ufacturer’s instructions. cDNA was generated using SuperScript III Reverse Transcriptase (Thermo Scientific). Quantitative real-time
PCR (qPCR) was performed using Maxima SYBRGreen/ROX qPCRMaster Mix (Thermo Scientific) on a Viia 7 real-time PCR system
(Thermo Scientific). Expression levels were normalized to human (HPRT1 or ACTIN) or murine (Hprt) housekeeping genes. Specific
primer sequences used are listed in the Key Resources Table.
Enzyme-Linked Immunosorbent Assay (ELISA)
Cell supernatant was assayed for murine TNF using eBioscence kit (Thermo Scientific) according to the manufacturer’s protocol.
Murine IFNb was measured using a custom-made protocol as previously reported (Roberts et al., 2007). The monoclonal rat anti-
mouse IFNb (USBiological Life Sciences; 138027) was used as a coating antibody, while the polyclonal rabbit anti-mouse IFNb
(PBL Assay Science; 32400-1) was used for detection. Recombinant mouse IFNb (carrier-free) (PBL Assay Science; 12401-1) was
used to generate a standard curve, peroxidase-conjugated AffiniPure F(ab’)2 fragment donkey anti-rabbit IgG (H+L) (Jackson Im-
muno Research; 711-036-152) was used for chemiluminescence, and PBS with 1% bovine serum albumin (BSA) was used as the
assay diluent.
Immunofluorescence
Immunofluorescence of NF-kB p65 and IRF3 nuclear translocation was performed as previously described (De Nardo et al., 2018a).
1-2 x105 BMDMs were plated in 8-well m-slides (Ibidi). Following experimentation cells were fixed with 4% paraformaldehyde for
10 min before blocking and permeabilizing cells (Block/Perm buffer: PBS, 10% (v/v) FCS, 0.5% Triton X-100) for 1 hr at room tem-
perature. Cell were then stained with anti-NF-kB p65 primary antibody (Cell Signaling Technology: clone C22B4, 4764, 1:100) or anti-
IRF3 (Cell Signaling Technology; clone D83B9, 4302, 1:100) overnight at 4C. The following day cells were stained with a secondary
goat anti-rabbit Alexa-647 antibody (Thermo Scientific; A-21244, 1:1000) before nuclear staining with DAPI (1 mM) for 5-10 min at
room temperature. Between steps cells were washed 3 times with Block/Perm buffer or PBS. Imaging was performed using a Zeiss
LSM 780 confocal microscope; 3x3 tile scans were taken for each experimental condition using a 63x oil objective with Immersol
518 F (Zeiss) and acquired with ZEN 2012 version 8.1 software (Zeiss). Image channels were merged before conversion to TIFF using
FIJI software. Quantification of nuclear staining was performed using FIJI software by identifying DAPI positive nuclei and measuring
the mean fluorescent intensity of the Alexa-647 channel within each nucleus.
QUANTIFICATION AND STATISTICAL ANALYSIS
Analyses were performed with Prism (GraphPad Software) and data are typically presented as the mean +SEM, where a p
value < 0.05 was considered significant as determined by paired or unpaired two-tailed Student t tests or a Mann Whitney test as
indicated in the specific figure legends.
DATA AND CODE AVAILABILITY
No datasets or code were generated in this study.
Cell Reports 31, 107492, April 7, 2020 e6
Cell Reports, Volume 31
Supplemental Information
TBK1 and IKKε Act Redundantly to Mediate
STING-Induced NF-kB Responses in Myeloid Cells
Katherine R. Balka, Cynthia Louis, Tahnee L. Saunders, Amber M. Smith, Dale J.
Calleja, Damian B. D'Silva, Fiona Moghaddas, Maximilien Tailler, Kate E. Lawlor, Yifan
Zhan, Christopher J. Burns, Ian P. Wicks, Jonathan J. Miner, Benjamin T. Kile, Seth L.
Masters, and Dominic De Nardo





